New drug combo trial opens for Tough-to-Treat advanced cancers
NCT ID NCT06576037
Summary
This early-phase study is testing a new drug, CBP-1019, in combination with several other cancer therapies for people with advanced solid tumors that have spread. The main goals are to find safe dose levels and see if these combinations can help shrink tumors. The study is enrolling adults with specific types of advanced cancer, like pancreatic, colorectal, and prostate cancer, who have already tried standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.